Public-Private partnership models in France and in Europe;Modèles de partenariats Public-Privé en France et en Europe

Therapie

Volumn 61, Issue 4, 2006, Pages 325-334

  Demotes Mainard, Jacques ^a,b,f   Canet, Emmanuel ^c,d,e   Segard, Lionel ^b   Allain, H ^g   Amedee Manesme O ^h   Ayme S ^b   Boubekeur, K ⁱ   Chabrier, P E ^j   Clement B ^b   Collet, J P ^k   Deregnaucourt, J ^a   Habert Ortoli, E ^l   Halioua, E ^m   Hamelin, B ⁿ   Juillet, Y ^o   Lacombe, D ^p   Lassale, C ^o   Longuet, M ^a   Pletan, Y ^q   Vasmant, D ^r   Vincent, C ^s   more..

^a de l évaluation et des statistiques Drees   (France)

^b INSERM   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^d LEEM   (France)

^e EFPIA   (Belgium)

^f DGRI   (France)

^g Inst de Rech Contre le Cancer IRCC   (France)

^h Clubhouse   (France)

ⁱ Hoffmann Laroche Ltd

^j IPSEN   (France)

^k Gereq   (Canada)

^l ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^m Inserm Transfert ^*

ⁿ Astra Zeneca

^o LEEM   (France)

^p EORTC DATA CENTER   (Belgium)

^q Pfizer

^r Sanofi Aventis

^s DIF   (France)

more..

Author keywords

Biotechnology; Clinical trials; Drug development; Health; Pharmaceutical industry; Public private partnership

Indexed keywords

BIOTECHNOLOGY; BRAIN DISEASE; CANCER; CLINICAL PRACTICE; CLINICAL RESEARCH; CONFERENCE PAPER; DIABETES MELLITUS; DRUG INDUSTRY; EUROPE; FRANCE; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH SERVICE; INFLAMMATION; MEDICAL RESEARCH; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; COMPARATIVE STUDY; ECONOMICS; FINANCIAL MANAGEMENT; GOVERNMENT; HUMAN; NONBIOLOGICAL MODEL; ORGANIZATION AND MANAGEMENT; RESEARCH; REVIEW;

DRUG INDUSTRY; EUROPE; FINANCING, GOVERNMENT; FRANCE; GOVERNMENT; HUMANS; MODELS, ORGANIZATIONAL; RESEARCH; RESEARCH SUPPORT;

EID: 36549049342     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2006058     Document Type: Conference Paper

References (33)

1. Innovation or Stagnation? Challenge and Opportunity on the Critical Path to New Medical Products. www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
2. Zerhouni E. The NIH Roadmap. Science 2003; 302: 63-72
3. Zerhouni E. Translational and clinical science - time for a new vision. NEJM 2005; 353: 1621-3
4. Fischer A, Borensztein P, Roussel C. The Europen rare disease thertapeutic initiative. A PPP is promoting research on new treatments for rare diseases. PLoS Medicine 2005; 2: e243
5. Frantz S. PPPs succeeding in tackling neglected diseases. Nature Rev Drug Discov 2005; 4: 796
6. Rawlins MD. Cutting the cost of drug development ? Nature Rev Drug Discov 2004; 3: 360-4
7. Ray WA, Stein CM. Reform of drug regulation - beyond an independent drug-safety board. NEJM 2006; 354: 194-200
8. http://www.medichildren.net/
9. Donnelly F, Jehenson P. European Technology Platform on Innovative Medicines. Int J Pharm Med 2005; 19: 153-61
10. SRA on http://europa.eu.int/comm/research/fp6/index_en.cfm?p=1_innomed
11. http://www.agence-nationale-recherche.fr
12. Stossel TP. Regulating acaademic-industrial research relationships - solving problems or stifling progress ? NEJM 2005; 353: 1060-5
13. http://www.orphanxchange.org/
14. http://www.pactepourlarecherche.fr/presse/2005/aaccarnot.pdf
15. http://www.competitivite.gouv.fr
16. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates ? Nature Rev Drug Discov 2004; 3: 711-5
17. Nissim A. Gofur Y, Vesselier S et al. Methods for targeting biologicals to specific disease sites. Trends Mol Med 2004; 10: 269-74
18. Fishman MC, Porter JA. A new grammar for drug discovery. Nature 2005; 437: 491-3
19. Singer E. Personalized medicine prompts push to redisgn clinical trials. Editorial, Nature Med 2005; 11: 462
20. The Royal Society. Personalised medicines hopes and reality. September 2005, pp 1-52. Access through http://www.royalsoc.ac.uk/document.asp?id=3780
21. Couvreur P et al. EUFEPS report : contribution of academic research to discovery and development of medicines : current status and future opportunities. Eur J Pharm Sci 2005; 24: 245-52
22. Marionnet AV. PME, innovations technologiques et secteurs d'application. Pharma-Biotech. OSEO-ANVAR. Direction Technologie Projets Européens, pp 1-43 (2004)
23. http://www.eortc.be
24. http://www.gereq.net
25. http://www.orpha.net
26. Demotes-Mainard J, Ohmann C : European Clinical Research Infrastructures Network : promoting harmonisation and quality in European clinical research. Lancet 2005; 365: 107-108
27. Demotes-Mainard J. et al. How to exploit existing assets and resources in Europe ? Report of the stakeholders forum on 'How to establish a European Technology Platform for innovative medicines'. Barcelona, April 21-22 (2005)
28. LEEM/AD Little. Optimisation de l'attractivité de la France pour la production biologique. Comité Biotechnologie du Leem, 28 novembre 2005
29. Demotes-Mainard J, Chêne G, Libersa C, Pignon JP : Clinical research infras tructures and networks in France : report on the trench ECRIN workshop. Thérapie 2005; 60: 183-99
30. Clément B, Grimaud JA, Deleuze JF, Postaire E. Le réseau des Centres de Ressources Biologiques Humains. Une infrastructure essentielle pour la recherche biomédicale en Europe. Thérapie 2005; 60: 351-4
31. Fitzgerald GA. Anticipating change in drug development : the emerging era of translational medicine and therapeutics. Nature Rev Drug Discov 2005; 4: 815-8
32. Vlahakes GJ. The value of phase 4 clinical testing. NEJM 2006; 354: 413-5
33. Remuzzi G, Schieppati A, Boissel JP, Garattini S, Horton R: Independent clinical research in Europe. Lancet 2004; 364: 17232-6